Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

60 Degrees Pharmaceuticals Inc. SXTP

Healthcare  —  Biotechnology
1.17 0.02 1.74% as of 25 Sep
Market cap
$4.1M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

60 Degrees Pharmaceuticals Inc. (SXTP) Business Profile

Updated before January 2025

Company Overview

60 Degrees Pharmaceuticals Inc. (SXTP) is a biopharmaceutical company dedicated to developing and commercializing innovative treatments for infectious diseases and other unmet medical needs. Founded in 2010, the company is headquartered in Washington, D.C., and has established itself as a leader in the development of therapies for tropical and travel-related diseases. The company was founded by Dr. Geoffrey Dow, who also serves as the CEO. Under his leadership, SXTP has focused on addressing global health challenges by creating accessible and effective treatments for diseases that disproportionately affect underserved populations.

SXTP operates with a mission to improve global health outcomes by providing affordable and effective solutions for infectious diseases. The company collaborates with government agencies, non-profit organizations, and private sector partners to advance its research and development efforts. Its leadership team comprises experienced professionals with expertise in pharmaceuticals, public health, and global health policy.

Core Business Segments

SXTP focuses on the development and commercialization of pharmaceutical products targeting infectious diseases. The company’s core business segments include:

1. Tropical Disease Treatments

  • Arakoda® (tafenoquine): A flagship product of SXTP, Arakoda® is an FDA-approved antimalarial drug designed for the prevention of malaria in adults. It is particularly effective for travelers visiting malaria-endemic regions and offers a convenient dosing regimen compared to traditional antimalarial medications.
  • Other Malaria-Related Research: SXTP is actively involved in research to develop additional therapies for malaria prevention and treatment, addressing the growing need for innovative solutions in this area.

2. Travel-Related Disease Solutions

  • SXTP develops and markets products aimed at preventing and treating diseases commonly encountered by travelers, such as dengue fever, chikungunya, and other vector-borne illnesses.
  • The company is exploring partnerships to expand its portfolio of travel-related disease solutions, ensuring that travelers have access to effective preventive measures.

3. Pipeline Products

  • SXTP has a robust pipeline of investigational drugs targeting other infectious diseases, including neglected tropical diseases. These products are in various stages of clinical development and aim to address significant unmet medical needs.

Business Model

SXTP operates on a business model that integrates research, development, and commercialization of pharmaceutical products. The company generates revenue through:

  • Product Sales: Revenue is primarily derived from the sale of Arakoda® and other pharmaceutical products.
  • Partnerships and Collaborations: SXTP collaborates with government agencies, non-profits, and private organizations to fund its research and development efforts. These partnerships often include licensing agreements and milestone-based payments.
  • Grants and Funding: The company secures funding from global health organizations and government agencies to support its mission of addressing infectious diseases.

SXTP’s business model emphasizes affordability and accessibility, ensuring that its products reach underserved populations in low- and middle-income countries.

Strategic Direction

SXTP is committed to expanding its product portfolio and addressing emerging global health challenges. Key strategic priorities include:

  • Pipeline Expansion: The company is investing in the development of new therapies for infectious diseases, including dengue fever, Zika virus, and other neglected tropical diseases.
  • Global Market Penetration: SXTP aims to increase the availability of its products in malaria-endemic regions, particularly in Africa and Southeast Asia.
  • Sustainability Goals: The company is focused on sustainable manufacturing practices and reducing its environmental footprint.
  • Digital Health Integration: SXTP is exploring the integration of digital health technologies to enhance disease prevention and treatment outcomes.

Competitive Landscape

SXTP operates in a competitive market, facing competition from both large pharmaceutical companies and smaller biotech firms. Key competitors include:

  • GlaxoSmithKline (GSK): A major player in the antimalarial drug market, GSK offers products such as Malarone® and has a strong presence in global health initiatives.
  • Novartis: Known for its antimalarial drug Coartem®, Novartis is a significant competitor in the malaria treatment space.
  • Biotech Startups: Smaller companies focusing on tropical and travel-related diseases also compete with SXTP by developing innovative therapies.

Despite the competition, SXTP differentiates itself through its focus on affordability, accessibility, and partnerships with global health organizations.

Risk Factors

SXTP faces several risks that could impact its operations and financial performance:

  • Market Dependence: The company relies heavily on the success of Arakoda® for revenue generation. Any decline in demand for this product could adversely affect its financial performance.
  • Regulatory Challenges: The pharmaceutical industry is highly regulated, and delays in obtaining regulatory approvals for new products could hinder SXTP’s growth.
  • Supply Chain Disruptions: Dependence on third-party manufacturers and suppliers exposes the company to risks related to supply chain disruptions.
  • Competition: Intense competition from larger pharmaceutical companies and biotech startups could impact SXTP’s market share.
  • Global Health Crises: Pandemics and other global health emergencies could disrupt SXTP’s operations and supply chains.

Recent Developments

SXTP has made significant strides in recent years, including:

  • FDA Approval of Arakoda®: The approval of Arakoda® marked a major milestone for the company, establishing it as a leader in malaria prevention.
  • Partnerships with Global Health Organizations: SXTP has partnered with organizations such as the World Health Organization (WHO) and the Bill & Melinda Gates Foundation to advance its research and development efforts.
  • Expansion into New Markets: The company has expanded its presence in malaria-endemic regions, increasing access to its products.
  • Research on Emerging Diseases: SXTP is actively involved in research to develop therapies for emerging infectious diseases, including dengue fever and Zika virus.

Investment Considerations

Investors considering SXTP should weigh the following strengths and risks:

Strengths:

  • Innovative Product Portfolio: SXTP’s focus on tropical and travel-related diseases positions it as a leader in a niche market.
  • Strong Partnerships: Collaborations with global health organizations enhance the company’s credibility and funding opportunities.
  • Growth Potential: The increasing demand for malaria prevention and treatment solutions presents significant growth opportunities.

Risks:

  • Market Dependence: Heavy reliance on Arakoda® for revenue generation poses a risk to the company’s financial stability.
  • Regulatory Hurdles: Delays in obtaining regulatory approvals for new products could impact growth.
  • Competitive Pressure: Intense competition from larger pharmaceutical companies could limit market share.

Conclusion

60 Degrees Pharmaceuticals Inc. (SXTP) is a pioneering biopharmaceutical company addressing critical global health challenges. With a focus on tropical and travel-related diseases, the company has established itself as a leader in the development of innovative therapies. While it faces risks related to market dependence and competition, SXTP’s strong partnerships, innovative product portfolio, and commitment to global health position it for long-term growth. As the demand for effective solutions to infectious diseases continues to rise, SXTP is well-positioned to capitalize on emerging opportunities and expand its impact on global health outcomes.